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Abstract
Background Pancreatic ductal adenocarcinoma (PDAC) is a particularly lethal malignancy partly due to frequent, severe ca-
chexia. Serum activin correlates with cachexia and mortality, while exogenous activin causes cachexia in mice.
Methods Isoform-specific activin expression and activities were queried in human and murine tumours and PDAC models.
Activin inhibition was by administration of soluble activin type IIB receptor (ACVR2B/Fc) and by use of skeletal muscle specific
dominant negative ACVR2B expressing transgenic mice. Feed-forward activin expression and muscle wasting activity were
tested in vivo and in vitro on myotubes.
Results Murine PDAC tumour-derived cell lines expressed activin-βA but not activin-βB. Cachexia severity increased with
activin expression. Orthotopic PDAC tumours expressed activins, induced activin expression by distant organs, and produced
elevated serum activins. Soluble factors from PDAC elicited activin because conditioned medium from PDAC cells induced
activin expression, activation of p38 MAP kinase, and atrophy of myotubes. The activin trap ACVR2B/Fc reduced tumour
growth, prevented weight loss and muscle wasting, and prolonged survival in mice with orthotopic tumours made from
activin-low cell lines. ACVR2B/Fc also reduced cachexia in mice with activin-high tumours. Activin inhibition did not affect
activin expression in organs. Hypermuscular mice expressing dominant negative ACVR2B in muscle were protected for weight
loss but not mortality when implanted with orthotopic tumours. Human tumours displayed staining for activin, and expression
of the gene encoding activin-βA (INHBA) correlated with mortality in patients with PDAC, while INHBB and other related fac-
tors did not.
Conclusions Pancreatic adenocarcinoma tumours are a source of activin and elicit a systemic activin response in hosts. Hu-
man tumours express activins and related factors, while mortality correlates with tumour activin A expression. PDAC tumours
also choreograph a systemic activin response that induces organ-specific and gene-specific expression of activin isoforms and
muscle wasting. Systemic blockade of activin signalling could preserve muscle and prolong survival, while skeletal muscle-
specific activin blockade was only protective for weight loss. Our findings suggest the potential and need for gene-specific
and organ-specific interventions. Finally, development of more effective cancer cachexia therapy might require identifying
agents that effectively and/or selectively inhibit autocrine vs. paracrine activin signalling.
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Introduction
Cancer cachexia is a multifactorial syndrome with progressive
weight loss mainly resulting from reduction of skeletal muscle
and fat mass; other cachexia-associated clinical manifesta-
tions include chronic inflammation, anorexia, and fatigue.1–3
Simply increasing food intake or nutritional support is inade-
quate to reverse the cachectic state. Patients with cancer ca-
chexia respond poorly to anti-cancer treatments including
chemotherapy and radiotherapy and experience increased
treatment toxicity. Lethality of pancreatic ductal adenocarci-
noma (PDAC) is due in large part to the frequent occurrence
of severe cachexia in patients with PDAC. Currently, there are
no approved, effective therapeutics to treat cachexia, despite
many promising pre-clinical studies.
Activin proteins have been implicated in cancer cachexia.
Activins are members of the transforming growth factor-beta
(TGF-β) superfamily and play multiple biological roles includ-
ing regulation of development, homeostasis, tissue repair,
and inflammation.4–8 Activins are composed of two polypep-
tide subunits, each being encoded by a separate gene, sub-
unit βA (gene Inhba), βB (Inhbb), βC (Inhbc), and βE (Inhbe).
Two βA or two βB form activin A or activin B, respectively,
while one βA and one βB form activin AB.9 Activin βC10–12
and βE13 were discovered more recently and have been
linked with cachexia,14,15 although their roles are less under-
stood. Deregulated activin A is often observed in various ma-
lignancies including pancreatic cancer,6,16–28 showing
overexpression in tumours or elevation in blood. This sug-
gests that activin A has potential endocrine effects on the
host organs. Elevated plasma activin A level is also docu-
mented with cachexia and mortality in PDAC.29,30 Activin B
has received much less attention regarding its role in cancer
or cancer cachexia.31–33 Experimentally, exogenous activin in-
duces weight loss and muscle wasting in mice,27,28 while in-
jection of a soluble activin receptor or activin-receptor
blocking antibody induces skeletal muscle hypertrophy and
prevents or slows cachexia in mice with cancer or other mus-
cle wasting conditions.34,35
Given activin A deregulation in cancer and likely its sys-
temic impact on host biology, we aimed to investigate activin
expression and cachexia in murine models of PDAC and in pa-
tients and to evaluate the therapeutic utility of blocking the
activin receptor ACVR2B-mediated signalling pathway.
Materials and methods
Ethics
The authors certify that they comply with the ethical guide-
lines for authorship and publishing of the Journal of Cachexia,
Sarcopenia and Muscle.36 All mouse studies were approved
by the Institutional Animal Care and Use Committee at Indi-
ana University School of Medicine and in compliance with
the National Institutes of Health Guidelines for Use and Care
of Laboratory Animals. Human tumour specimens were ob-
tained under an IRB approved protocol number 1312105608
from patients undergoing surgery for pancreatic cancer at In-
diana University.
Pancreatic cancer cell lines
Pancreatic cancer cells, KPC32043, KPC32047, and KPC32908
(gifted by David Tuveson, Cold Spring Harbor Laboratories) de-
rived from the genetically engineered KrasG12D;Trp53R172H;
Pdx1::Cre mouse were maintained in Dulbecco’s modified Ea-
gle’s medium (DMEM)medium. All media were supplemented
with 10% fetal bovine serum and 1% penicillin/streptomycin.
Conditioned medium (CM) was collected from confluent
cultures.
Effects on myotube size
C2C12 cells (ATCC, Manassas, VA, USA) were maintained in
DMEM with 10% fetal bovine serum and 1%
penicillin/streptomycin. Myoblast differentiation to
myotubes was induced by shifting confluent cultures to dif-
ferentiation medium (DM), consisting of DMEM with 2%
horse serum. DM was replaced every day for 6 days. KPC cell
CM was added to C2C12 myoblast or 4-day-old differentiated
myotube cultures at 25%, 50%, or 75% in DM for 24 or 48 h.
Cultures were fixed in 4% paraformaldehyde and perme-
abilized in 1% Triton X-100 at room temperature, followed
by blocking in Sea Block Blocking Buffer (Thermo Fisher Scien-
tific, Waltham, MA, USA) supplemented with 0.2% Tween 20.
Fixed myotubes were incubated with myosin heavy chain
(MyHC) primary antibody (1:100, Developmental Studies Hy-
bridoma Bank, Iowa City, IA, USA) and then with Alexa Fluor
488-conjugated anti-mouse secondary antibody (1:1000,
Invitrogen, Carlsbad, CA, USA). Nuclei were stained with 1
μg/mL 4′,6-diamidino-2-phenylinole (Calbiochem, Millipore
Sigma, Burlington, MA, USA). Images were acquired at 10×
using a monochrome (MRm) Zeiss AxioCam camera mounted
on a Zeiss Axio Observer.Z1 inverted microscope. Fifteen
fields from each well were randomly selected at imaging ac-
quisition, and three wells per experimental condition gave
45 fields from which >200 qualified myotubes per well and
condition were measured at or near the middle of isolated,
long, multinucleate myotubes avoiding regions of clustered
nuclei, using Fiji (https://fiji.sc). The average diameter of
myotubes per condition was calculated and expressed as
mean ± SD.
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Mice
Mice were housed up to five per cage in a pathogen-free fa-
cility on a 12 h light cycle, with ad libitum access to
autoclaved food and sterile water. At the end of experiments,
mice were euthanized under isoflurane general anaesthesia
with cardiac puncture for collection of platelet-poor plasma.
Tissues were collected and weighed, then snap frozen in liq-
uid nitrogen for protein or RNA extraction, and muscle frozen
in cold 2-methylbutane for cryosectioning or fixed in 10%
neutral buffered formalin solution. Frozen plasma and tissue
were stored at 80°C.
Pancreatic ductal adenocarcinoma models
For the orthotopic cancer models, KPC pancreatic cancer cells
(500 000 or 5million as indicated) were injected into the pan-
creas of ~10-week-old wild-type (WT) C57BL/6 male mice
(Jackson Laboratory, Bar Harbor, ME, USA). Briefly, mice were
anaesthetized by inhalation of isoflurane, and a 1.2 cm
lengthwise incision into the upper left quadrant was made.
The cell suspension (40 μL) was injected into the pancreas,
and the cavity was closed with suture and clips. Controls were
similarly treated with the exception of cell injection. Mice
were treated twice daily for 48 h with buprenorphine for
pain, and wound clips were removed at 7 days. Mice were
weighed daily and euthanized under isoflurane anaesthesia
when they reached the pre-designated endpoint. Body com-
position, mouse activities, and muscle strength were moni-
tored weekly or at the end of experiments. The genetically
engineered mouse model of PDAC, KPC (KrasG12D;
Trp53R172H;Pdx1-Cre) was generated by crossing LSL-KrasG12D
mice with LSL-p53R172H mice (National Cancer Institute), pro-
ducing LSL-KrasG12D;LSL-p53R172H (i.e. KP), which was then
crossed with Pdx1-Cre (Jackson Laboratory) that expresses a
pancreas-specific Cre recombinase, giving rise to KPC mice
that develop tumours in the pancreas. The KPC genetically
engineered mouse model mimics human PDAC by introducing
a high degree of genomic instability due to point mutations in
the oncogene Kras and the tumour suppressor gene p53.37
For activin inhibition, C57BL/6J mice bearing orthotopic KPC
tumours were treated with either phosphate buffered saline
(vehicle control) or ACVR2B/Fc (10 mg/kg) at the designated
intervals. Hypermuscular MLC-dnACVR2B mice were a gift
from Se-Jin Lee. These over-express in skeletal muscle a dom-
inant negative ACVR2B lacking the intracellular domain. Male
and female mice and WT littermates were orthotopically im-
planted with murine KPC cells (5 × 105 per mouse) at age of
10 weeks.
Activity was assessed by counting horizontal and vertical
movements of individual mice in a fresh cage placed within a
VersaMax AccuScan activity monitor (Columbus Instruments,
Columbus, OH, USA) recording for 30 min. Grip strength was
assessed using a wire mesh grid and all four limbs, repeated
three times on each mouse with peak force recorded in grams
using an attached force transducer (Columbus Instruments).
Activity on an inverted grid was used to assess combined fore-
paw and hind paw strength. Mice were placed on a wire grid
that was then inverted over a foam pad, resulting in mice
hanging upside-down; the number of times the mice crossed
into marked quadrants was recorded (Figure 5B). To evaluate
treatment effects on indicators of wellness/distress, an 11-
point scoring system based upon Paster et al.38 plus body con-
dition scoring was used, where 11 was normal and <3 consis-
tent with imminent death. Factors assessed included
appearance (2 = bright eyes, well-groomed shiny hair; 1 = dull
fur, lack of grooming; 0 = pilorerection, hunched back, rough
coat, abnormal posture), behaviour (2 = active, interactive,
alert; 1 = isolated, decreased activity, decreased alertness; 0
= immobile, weak, vocalizations), provoked behaviour (3 =
quickly moves away; 2 = slow to move; 1 = moves after a short
period; 0 = does not move), clinical signs (2 = normal body
temperature/respiratory rate; 1 = decreased body
temperature/respiratory rate; 0 = hypothermia, markedly re-
duced respiratory rate), and body habitus (2 = normal; 1 = thin,
0 = emaciated).
The endpoint for euthanasia was dependent on the aims of
studies. For tissue endpoints to study response to
tumour/therapeutic intervention, all mice were euthanized
when either group reached an average score of 3 on the
11-point scale. For studies of therapeutic intervention effects
on survival (Figures 5C and 6B), mice were euthanized when
moribund.
Quantitative real-time polymerase chain reaction
Total RNA was extracted using the QIAzol Lysis Reagent and
miRNeasy Mini Kit (217004, Qiagen) and reverse-transcribed
into complementary DNA (cDNA) using the TaqMan Reverse
Transcriptase Reagents (4366596, Life Technologies, Carls-
bad, CA, USA) or the Verso cDNA Synthesis Kit (AB1453B,
Thermo Scientific), following the manufacturer’s instructions.
Equal amounts of cDNA were subjected to quantitative real-
time polymerase chain reaction (RT–qPCR) performed using
the TaqMan Universal Master Mix II with UNG on the
LightCycler Instrument (Roche Life Science, Indianapolis, IN,
USA). Gene-specific TaqMan PCR-based gene expression as-
says were from Life Technologies, including Inhba
(Mm00434339_m1), Inhbb (Mm03023992_m1), Trim63/
MuRF-1 (Mm01185221_m1), Fbxo32/MAFbx/Atrogin1
(Mm00499523_m1), Mstn (Mm01254559_m1), Gdf15
(Mm00442228_m1), Gdf11 (Mm1159973_m1), and Rn18s
(Mm03928990_g1). Ct values for target and housekeeping
genes were used to calculate relative transcript abundance
using the ΔΔCt method. Data were presented as the mean
fold change.
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Immunohistochemistry
Immunohistochemistry (IHC) was performed on formalin-
fixed, paraffin-embedded 5 μm tissue sections. Sections were
deparaffinized and rehydrated, then heated in 0.01 M citrate
buffer (pH 6.0) to retrieve antigens. Endogenous peroxidase
was quenched in 3% H2O2. Sections were incubated with
the specific primary antibodies to activin A/INHBA from
R&D Systems (AF338) or to activin B/INHBB from
antibodies-online (ABIN952903) at 1:100 in Odyssey Blocking
Buffer (927-50010) and then with peroxidase conjugated sec-
ondary antibodies, ImmPRESS anti-goat (MP740550) or
ImmPRESS anti-rabbit (MP-7401) from Vector Laboratories,
Burlingame, CA, USA. The immunostaining was visualized
with ImmPACT DAB (SK-4105) from Vector Laboratories.
Thereafter, the sections were counterstained with
haematoxylin.
Immunohistochemistry stain imaging and
quantification
Images shown were acquired at 20× using a colour Zeiss
AxioCam camera mounted on a Zeiss Axio Observer.Z1
inverted microscope. For image quantification, whole slide im-
ages were taken using Aperio Scan Scope CS at 20×. The Posi-
tive Pixel Count algorithm was used to quantify the amount of
a specific stain present in a scanned slide image. A range of col-
our (range of hues and saturation) and three intensity ranges
(weak, positive, and strong) were masked and evaluated. The
algorithm counted the number and intensity sum in each in-
tensity range, along with three additional quantities: average
intensity, ratio of strong/total number, and average intensity
of weak positive pixels. The algorithm had a set of default in-
put parameters when first selected—these inputs have been
pre-configured for brown colour quantification in the three in-
tensity ranges (220-175, 175-100, and 100-0). Pixels, which
were stained but did not fall into the positive-colour specifica-
tion, were considered negative-stained pixels—these pixels
were counted as well, so that the fraction of positive to total
stained pixels was determined. For the tissue microarray IHC,
three pathologists scored all biopsies for staining intensity
and histopathology diagnosis, blinded to each other’s scores
and supplier diagnosis.
Enzyme-linked immunosorbent assay
Activin A enzyme-linked immunosorbent assay (ELISA) was
performed using the activin A DuoSet (DY338, R&D Systems,
Minneapolis, MN, USA), per manufacturer’s protocol. In brief,
96-well plates were coated with the capture anti-activin A an-
tibody overnight at room temperature, and non-specific bind-
ing was blocked with diluent followed by sample (CM or
mouse plasma) addition and incubation. Biotinylated anti-
activin A detection antibody was added, which were subse-
quently incubated with streptavidin–horseradish peroxidase.
Substrate solution was added to produce a visible signal,
and the optical density of the signal was determined using a
microplate reader (BioTek, Winooski, VT, USA).
Western blotting analysis of C2C12 myotubes
C2C12 myotubes were lysed in RIPA buffer. Extracted cell ly-
sates were subjected to 4–15% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) and transferred
onto nitracellulose membranes (#1620112, Bio-Rad, Hercules,
CA, USA), followed by immunoblotting using primary antibod-
ies: phospho-p38MAPK (Thr180/Tyr182) (4511) and total p38
MAPK (8690) from Cell Signaling Technology, Danvers, MA,
USA; Smad3 (S423 + S425) (ab52903), total Smad3
(ab40854), and GAPDH (ab9484) from Abcam, Cambridge,
UK, USA, and tubulin from the Development Studies Hybrid-
oma Bank at the University of Iowa. Secondary antibodies
were as follows: IRDye 800CW goat anti-rabbit IgG (926-
32211), IRDye 680RD goat anti-rabbit IgG (925-68071), IRDye
680LT goat anti-mouse IgG2b-specific (926-68052), and IRDye
680LT goat anti-mouse IgG1-Specific (926-68050) from LI-
COR Biosciences, Lincoln, NE, USA. Signal was detected using
a LI-COR Odyssey system.
ACVR2B/Fc preparation and purification
ACVR2B/Fc fusion protein was purified from CM of Chinese
hamster ovary cells (a gift from Se-Jin Lee, Johns Hopkins Uni-
versity School of Medicine) on Protein A Sepharose (GE
Healthcare, Chicago, IL, USA) and dialysed against 1× phos-
phate buffered saline using a Slide-A-Lyzer dialysis kit. The
dialysed protein was confirmed by western blotting using re-
combinant ACVR2B/Fc (R&D Systems) as a positive control.
Biological activity of the protein was assessed by confirming
a hypertrophic effect in muscle in normal C57BL/6J mice
(not shown).
Database analysis of human pancreatic cancer and
myostatin gene expression
Oncomine was accessed, and pancreatic cancer data sets
with normal controls were analysed.39 Clinical and RNAseq
data were downloaded from The Cancer Genome Atlas
(TCGA).40 For each of the genes of interest, the association
between abundance of gene expression and overall survival
was fitted by a Cox proportional hazards regression model.
Age, which significantly associated with overall survival
(0.0054), was adjusted in the regression. Statistical analysis
1086 X. Zhong et al.
DOI: 10.1002/jcsm.12461
Journal of Cachexia, Sarcopenia and Muscle 2019; 10: 1083–1101
was performed in R version 3.1.2. UALCAN was used for visu-
alization of gene association with survival.41 Expression of
myostatin (MSTN) was queried for human tissues in the GTEx
Portal (gtexportal.org) and across other cells and tissues via
Illumina BaseSpace Correlation Engine (illumina.com). The
data used for the analysis described in this manuscript
(Supporting Information, Figure S2) were all obtained from
the GTEx Portal and Illumina BaseSpace on 04/04/2019.
Statistical analysis
Two group comparisons were by unpaired Student’s t-test.
Comparison of multiple groups was by analysis of variance
followed by Tukey’s post-hoc test. For all analyses, the level
of significance was set at P < 0.05.
Results
Murine pancreatic ductal adenocarcinoma
tumour-derived cells expressed activin A, but not
activin B
Three PDAC cell lines, KPC32043, KPC32047, and KPC32908,
were analysed by RT–qPCR for expression of two activin β sub-
unit genes, Inhba and Inhbb. Compared with normal mouse
pancreas, Inhba mRNA increased by 52-fold (P < 0.001),
132-fold, and 551-fold (P < 0.0001), respectively (Figure 1A),
with highest expression in KPC32908 cells. Inhbb was unde-
tectable (data not shown). To determine whether the in-
creased Inhba expression leads to increase in βA subunit
secretion, we collected CM from KPC cell line cultures and
measured activin A by ELISA. Indeed, KPC cells secreted activin
Awith KPC32908 levels being 6.6-fold higher than KPC32047 (P
< 0.05) vs. undetectable levels in KPC32043 CM (Figure 1B).
We subsequently refer to these as activinhigh-KPC32908 and
activinlow-KPC32043 lines.
Pancreatic ductal adenocarcinoma cell lines elicited
expression of activin B from host stromal cells in an
orthotopic tumour model
We examined Inhba and Inhbb mRNA expression in PDAC ca-
chexia developing from orthotopic implantation of 5 million
KPC tumour cells into C57BL/6J male mice. Mice were eutha-
nized when they met specific veterinarian body condition
criteria of activity and appearance. In this trial, mice with
KPC32908 tumours were euthanized at 9 days, those with
KPC32047 at 13 days, and KPC32043 at 14 days (N = 4 or 5
per group). Tumour size at euthanasia was not different across
groups cell lines (one-way analysis of variance, 0.576). Com-
paredwith the normal pancreas from sham-operated controls,
the KPC32043, KPC32047, and KPC32908 tumours expressed
high levels of Inhba, with 201-fold, 85-fold, and 931-fold in-
crease, respectively, although due to large variance, only
KPC32047 met the statistical definition of significance (Figure
1C, left). These tumours also expressed Inhbb, with the highest
KPC32908 being ~10-fold greater than normal pancreas (Fig-
ure 1C, right). This differential expression pattern generally
agreed with that displayed by the original KPC cell lines,
namely, high levels of Inhba and low/no levels of Inhbb. To
confirm the presence of activin proteins in the PDAC tumour
tissue, we performed IHC staining with antibodies against
activin subunits. Both Inhibin βA and βB subunits were de-
tected in the tumour epithelial cells and in the stromal cells
of orthotopic PDAC tumours (Figure 1D) as well as in tumour
epithelial and stromal cells present in tumours from the genet-
ically engineered KPC model (Figure 1E). These results indicate
that PDAC tumour cells express activin A but that they also
elicit expression of activins from surrounding host cells. More-
over, tumour growth and systemic effects scaled with level of
activin expression by tumours.
There was a systemic functional decline with
orthotopic pancreatic ductal adenocarcinoma
tumours
We assessed the organ response to factors released by
activinLow-KPC32043 tumours over time and at the experi-
mental endpoint. Mouse body weights were monitored af-
ter intra-pancreatic implantation of 50 000 KPC cells, up
until the time of euthanasia at the specified humane end-
point. Tumour-bearing mice ceased gaining body weight
by 12 days and lost body weight over time. On the other
hand, the sham-operated mice steadily gained weight, lead-
ing to a final difference of approximately 9% between KPC
mice and sham controls (P < 0.001) (Figure 2A). Evaluation
of the final activity and body condition of the tumour-
bearing mice demonstrated significant reductions, P <
0.001 (Figure 2B) and P < 0.0001 (Figure 2C), respectively,
compared with the sham controls. Furthermore, KPC mouse
organ weights were significantly reduced (Figure 2D). Be-
cause the KPC tumour-derived cell lines release activin A
into the culture medium as shown in Figure 1B, the tumour
would be expected to release activin A into the blood sys-
tem. Indeed, activin A was increased by an 11.5-fold in
KPC32043 mouse plasma (P < 0.0001) (Figure 2E).
There was a systemic activin response to
orthotopic pancreatic ductal adenocarcinoma
tumours
Multiple organs responded to the presence of the PDAC tu-
mour by increasing activin expression. Inhba mRNA was
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significantly increased up to a few-fold in most of the or-
gans including the spleen, heart, fat, and kidney but
down-regulated in the liver and quadriceps skeletal muscle
(Figure 3A). However, all organs demonstrated increased
Inhbb expression (Figure 3B), and the magnitude of the in-
crease was generally much greater than that of Inhba in
the same tissues. The increased mRNA levels led to in-
creased activin proteins in these organs as detected by im-
munohistochemistry in the orthotopic Activinlow-KPC32043
(Figure 3C) and the orthotopic activinhigh-KPC32908 models
(Figure 3D). Consistent with this systemic, multi-organ
activin response being a general feature in pancreatic
cancer, the muscle, kidney, liver, and heart from genetically
modified KPC mice with autochthonic tumours also showed
strong staining for activins (Figure 3E), while low to no
staining was observed in normal genotype control tissues.
Pancreatic ductal adenocarcinoma cells express
factors that induced expression of activins and
atrophy of muscle cells
Because muscle wasting is the major feature of cancer ca-
chexia and activins are induced in distant organs by PDAC,
Figure 1 Murine PDAC tumour-derived cells express activin A but not activin B, while tumours express both activins A and B. (A) Quantitative RT–PCR
demonstrating varying levels of Inhba mRNA in cell lines: KPC32043, KPC32047, and KPC32908. Inhbb was undetectable (not shown). Data are pre-
sented as the mean fold change relative to normal mouse pancreas ± SD. (B) ELISA demonstrating activin A protein levels in the conditioned medium
(CM) collected from the culture of the three KPC cell lines. Data are presented as mean ± SD. (C) Quantitative RT–PCR demonstrating levels of Inhba
and Inhbb mRNA in pancreatic tumours generated by injection of the KPC cell lines into the pancreas of C57BL/6J mice. Triplicate replicate data are
compared with normal pancreas of sham-operated mice and presented as mean ± SEM (n = 3 tissues per condition). (D) Immunohistochemistry
(IHC) of activin A or activin B in pancreatic tumours from two orthotopic PDAC models (KPC32043 and KPC32908). (E) IHC of pancreatic tumours from
mice with genetic PDAC (KPC mice). Normal pancreas tissues were from sex-matched and age-matched mice with wild-type (WT) Kras and WT p53
alleles. Scale bar: 100 μm. *P < 0.05, ***P < 0.001, ****P < 0.0001.
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we examined whether factors released from tumour cells can
directly induce activin expression. Murine C2C12 cells were
used to model muscle. Myoblasts were exposed to 75% of
activinhigh-KPC32908 CM for 24 or 48 h, while 4-day-old dif-
ferentiated myotubes were exposed to 25%, 50%, or 75% of
KPC32908 CM for 48 h (Figure 4A). Inhba and Inhbb expres-
sions were assessed with RT–qPCR. CM significantly increased
Inhba and Inhbb in myoblasts and myotubes, compared with
their respective controls (Figure 4B), at levels that induced
myotube atrophy after 48 h of CM treatment (Figure 4C, left).
The average reductions in myotube diameter were statisti-
cally significant at all the three CM dilutions (25%, 50%, or
75%) in a dose-dependent manner; the higher the CM con-
centration, the more severe the atrophy (Figure 4C, right).
While Inhbb induction was consistent with skeletal muscle ex-
pression in vivo, the Inhba results are discrepant, suggesting
differences between the systems.
To understand whether the KPC cells might also activate
signalling downstream of activin receptors, we probed the
phosphorylation/activation states of Smad2, Smad3,
and p38 MAPK by western blotting analysis in myotubes
treated with 75% CM from activinhigh-KPC32908 or
activinlow-KPC32043 cells. No pSmad2 was detected in any
samples (not shown). Neither was Smad3 activated by CM
relative to growth media at any time points. However,
p38 MAPK activation was prominent at 15 and 30 min
(Figure 4D), consistent with the described signalling of
activins on C2C12 myotubes.42 The activation state
persisted through 1 and 5 h and disappeared by 24 h after
CM treatment (data not shown). Notably, there was a
much stronger p38 MAPK activation signal in cells
treated with activinhigh-KPC32908 CM than activinlow-
KPC32043 CM.
Activin trap in mice with activinlow pancreatic
ductal adenocarcinoma blocked weight loss and
prolonged survival
To determine whether blocking circulation activins would
alleviate cachexia, we treated mice with ACVR2B/Fc in the
lower Inhba-expressing, activinlow-KPC32043 orthotopic
mouse model. Administration of ACVR2B/Fc (10 mg/kg i.
p.) reduced body weight loss starting at approximately
two weeks after the first injection (Figure 5A, left). By the
end of the experiment, weight loss had been completely
prevented in the ACVR2B/Fc treatment group. ACVR2B/Fc
treatment also preserved body condition scoring (Figure
5A, right), hanging grid exploration activity (Figure 5B, left),
and open-field activity (Figure 5B, right). Survival was
Figure 2 There is a systemic functional decline and organ wasting due to PDAC. (A–D) Systemic changes in body weight, activity, body condition, and
organ weight in response to PDAC tumour developed by orthotopic injection of KPC32043 cancer cell line, compared with the sham-operated mice. (E)
Elevated activin A level in plasma from the tumour-bearing mice as determined by ELISA. Data are presented as mean ± SEM. **P < 0.01, ***P < 0.001,
****
P < 0.0001.
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prolonged by treatment; median survival was 29.5 days for
the ACVR2B/Fc treated mice vs. 25 days for the untreated
controls (P < 0.05, log–rank test) (Figure 5C). Skeletal mus-
cle, heart, and fat loss were attenuated, although the effect
on fat did not reach significance (Figure 5D). Tumour
growth was also attenuated ~30% (1763 ± 137.4 mg, n =
9 untreated vs. 1218 ± 114.5 mg, n = 10, treated, P
=0.07). Muscle from ACVR2B/Fc-treated mice showed
reduction in two muscle-specific E3 ligase genes, Atrogin-
1/MAFbx/Fbxo32 and Murf-1/Trim63 (Figure 5E, left) and
in the muscle growth inhibitor Mstn (Figure 5E, right) vs.
vehicle-only controls. Expression of Inhba and Inhbb was
not reduced by activin blockade (Figure 5E, right),
suggesting this is not an activin feed-forward loop but
rather that other factors not targeted by ACVR2B/Fc must
elicit activin expression.
Figure 3 There is a systemic activin response to PDAC. (A, B) Inhba or InhbbmRNA expression by quantitative RT–PCR in organs harvested at the study
endpoint from sham control and orthotopic KPC32043 tumour-bearing mice. Expression values in all organs for each gene were normalized to the value
from the control liver. IHC for activin A and activin B in organs from mice with (C) orthotopic KPC32043 tumours, (D) orthotopic KPC32908 tumours, or
(E) genetic PDAC (KPC mice). Data are presented as mean ± SEM. Scale bar: 100 μm.
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Activin trap in mice with activinhigh pancreatic
ductal adenocarcinoma blocked weight loss
without improving survival
We also administered ACVR2B/Fc in the higher Inhba-
expressing, activinhigh-KPC32908 orthotopic mouse model to
explore whether activin blockade could exert a therapeutic
role at higher levels of activin production. As in the activinlow
model, ACVR2B/Fc treatment prevented body weight loss
(Figure 6A), but unlike the prior experiment, ACVR2B/Fc did
not prolong survival (Figure 6B).
Skeletal muscle-specific activin blockade reduced
body weight loss without prolonging survival in
pancreatic ductal adenocarcinoma
Because ACVR2B/Fc administration inhibited cachexia in the
KPC orthotopic model, we queried whether ACVR2B activity
Figure 4 PDAC tumour cells express factors that induce muscle cell activin expression and atrophy. (A) Experimental scheme. (B) Quantitative RT–PCR
demonstrating induction of Inhba and Inhbb by 75% KPC32908 CM. (C) Immunofluorescence staining for myosin heavy chain in C2C12 myotube cul-
tures and quantification of myotube size (>200/condition) in growth medium GM, 25%, 50%, or 75% of KPC32908 CM. *P< 0.05, ***P< 0.001, ****P<
0.0001. Scale bar: 200 μm. (D) Western blot demonstrating activation of p38 MAPK by 75% CM from KPC32908 activinhigh and KPC32043 activinlow at
15 and 30 min after CM treatment.
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in skeletal muscle contributes to PDAC muscle wasting. We
used transgenic (Tg) MLC-dnACVR2B mice that express a skel-
etal muscle-specific, dominant negative ACVR2B that lacks
the kinase domain and thus blocks ACVR2B signalling43 and
compared them with WT littermates. Activinlow-KPC32043
cells were implanted in the pancreas. Body weights were
monitored daily and normalized to starting weight to account
for differences in size. There were no differences in relative
body weight between WT sham and Tg sham over the whole
experiment (Figure 7A). As previously, in WT mice activinlow-
KPC32043 tumours induced steady weight loss over 23 days
(Figure 7A), reaching 11.5% reduction from starting weight
(P < 0.01). However, Tg mice showed no body weight loss
compared with tumour-bearing WT mice and Tg sham con-
trols. We also evaluated activinhigh-KPC32908 tumours in Tg
and WT mice. As for activinlow tumours, there was no body
weight loss in activinhigh-KPC32908 tumour-bearing Tg mice.
Regardless, survival was not prolonged in Tg vs. WT mice with
Figure 5 Activin blockade in mice with activinlow PDAC cells via soluble activin receptor reduces weight loss and prolongs survival. (A) Body weights
after KPC32043 cell implantation into the pancreas and time points (arrows) of ACVR2B/Fc administration (10 mg/kg body weight via i.p.) (left) and
body condition scores at the end of the experiment (right). IBW, initial body weight measured on the day of cell implantation. (B) Mouse activity mea-
sured at the indicated time points (left) or at the end of experiment (right) showing a therapeutic effect of activin blockade. (C) Increased survival in
mice with KPC32043 tumours treated with ACVR2B/Fc (log–rank test). (D) Effect of activin blockade on organ mass. (E) Effect of activin blockade on the







0.001, ****P < 0.0001.
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activinhigh-KPC32908 tumours (Figure 7C). These results indi-
cate that muscle-specific inhibition of activin signalling was
protective against PDAC-induced muscle wasting but did not
promote survival.
Activin proteins are expressed by human
pancreatic ductal adenocarcinoma tumours
To determine the relevance to human PDAC, we evaluated
activin expression in human tumours from patients treated
at our institution. Antibodies to activin βA and βB both de-
tected strong expression in human PDAC tumour sections
(shown are representative images), compared with normal
adjacent pancreas (Figure 8A, top panel). Staining was not
significantly different between tumour and stroma, although
both showed wide ranges of staining intensities. We also
stained a commercially available pancreatic tissue microarray
with the same antibodies and staining protocol, although
with hand scoring by three pathologists. Both activin A and
activin B expressions were significantly increased in PDAC tu-
mour compared with the normal pancreas (P < 0.0001) (Fig-
ure 8B). Consistent with these findings, an Oncomine query of
studies in pancreatic cancer demonstrates three-fold to 33-
fold increases in INHBA gene expression in tumours vs. con-
trols (Table 1), while INHBB showed no significant results.
Tumour INHBA but not INHBB correlates with
reduced survival in patients with PDAC
Our studies indicate that tumour-expressed activin A may
play an important role in human PDAC disease. Indeed,
analysis of TCGA pancreatic adenocarcinoma data set
demonstrates that high INHBA expression associated with
shorter overall survival vs. low/medium expression (Table 2,
Figure 9). Expression by stage was not statistically informa-
tive, because 146 of the 162 samples comprising this data
set represent Stage 2 disease, consistent with tissue collec-
tion from surgical resection of the tumour (Supporting In-
formation, Figure S1). In contrast, no association with
mortality was shown for expression of Inhibin-α (INHA),
activin B (INHBB), GDF-15 (GDF15), activin binding proteins
Follistatin (FST) and FLRG (FSTL3), or any of the receptors
ACVR2A, ACVR2B, ACVR1B, or ACVR1C (not shown), either
by analysis using dichotomous (high vs. low/medium)
(Figure 9) or continuous variables (Table 2). Expression of
two related TGF-β family proteins that also share binding
to ACVR2B, myostatin (MSTN), and GDF-11 (GDF11) actually
Figure 6 Activin blockade in mice with activinhigh PDAC cells via soluble activin receptor reduces weight loss without improving survival. (A) Body
weights after KPC32908 cell implantation into the pancreas and time points (arrows) of ACVR2B/Fc administration (10mg/kg body weight via i.p.) (left)
and body condition scores at the end of the experiment (right). IBW, initial body weight measured on the day of cell implantation. (B) Survival in mice
with KPC32908 tumours treated with ACVR2B/Fc (log–rank test).
****
P < 0.0001.
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associated with improved survival (Table 2). While
myostatin is generally considered to be muscle specific,
the extra-muscular expression of MSTN by pancreatic tu-
mours is consistent with its expression in other tissues, in
transformed fibroblasts, and in cancer cell lines (Supporting
Information, Figure S2A–C). There was insufficient data to
assess another ACVR2B-binding family member, GDF-2/
BMP-9 (not shown).
Discussion
The myriad functions of activin A in multiple biological pro-
cesses such as reproduction and inflammation are well
established although its roles in cancer and cancer cachexia
are only more recently explored. Understanding its role in
pancreatic cancer and associated wasting is vital because
PDAC cachexia reduces treatment efficacy and quality and
Figure 7 Skeletal muscle-specific blockade of activin signalling via expression of dnACVR2B in MLC-dnACVR2B mice prevents PDAC-induced weight loss
but does not improve survival. (A) Body weights of KPC32043 pancreatic tumour-bearing wild-type (WT) C57BL/6 mice (WT + KPC32043) or transgenic
(Tg) MLC-dnACVR2B mice (Tg + KPC32043), normalized to each mouse’s own initial body weight. (B) Body weights of KPC32908 pancreatic tumour-
bearing wild-type (WT) C57BL/6 mice (WT + KPC32908) or transgenic (Tg) MLC-dnACVR2B mice (Tg + KPC32908), normalized to each mouse’s own
initial body weight. (C) Survival of WT vs. Tg mice with KPC32908 tumour cells is not different (log–rank test). Mean ± SEM. *P < 0.05, **P < 0.01.
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length of life.44 Substantial data document an association of
activin and cachexia in pancreatic cancer and other can-
cers.23,29,30 As well, a large body of literature demonstrates
a protective effect of activin receptor-based inhibitors across
a spectrum of experimental and pre-clinical cachexia cancer
models34,35,45 isolated chemotherapy,46 or the combination
of cancer and chemotherapy.47 A clinical trial (https://
clinicaltrials.gov/ct2/show/NCT01433263) of an anti-activin
receptor antibody has also been carried out in 57 patients
with late stage lung and pancreatic cancer, although the re-
sults have not been formally reported in the literature. Inter-
pretation of those results and ultimately effective targeting of
Figure 8 Activin proteins are expressed by human PDAC tumours. (A) Representative IHC for activin A and activin B in tumour tissues and quantifica-
tion from PDAC patients from Indiana University (IUH). (B) Representative images and quantification of IHC for activin A and B in a PDAC cancer tissue
microarray (TMA). Normal pancreas (n = 8) and PDAC tumour (n = 27). Mean ± SEM. Scale bar: 100 μm. ****P < 0.0001.
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activin in PDAC will require an intimate understanding of the
mechanisms of its expression and action in tumour cells, in
the tumour microenviroment, and in the host body.
In the present study, we have identified a systemic, multi-
ple organ activin response to PDAC tumours both in pre-
clinical models and in patients. While PDAC tumour cells
and tumours expressed a high level of activin A and activin
A expression was associated with mortality, multiple distant
organs expressed both activin A and activin B in response to
a PDAC tumour in the pancreas. PDAC tumour-derived factors
are causally involved in eliciting activin expression and muscle
wasting because direct exposure of PDAC cell CM on
myotubes caused both activin expression and a reduction in
myotube size. In vivo, activin blockade using the soluble re-
ceptor ACVR2B/Fc reduced tumour growth and associated
PDAC cachexia in both models and prolonged survival in the
less-aggressive, activinlow mouse model. This protection was
not mediated by reduced systemic activin production, appar-
ently, because activin expression in muscle remained high,
implicating non-activin factors in the systemic response.
Furthermore, skeletal muscle-specific inhibition of activin sig-
nalling using the MLC-dnACVR2B mouse model prevented
PDAC-induced weight loss, although it did not improve
survival. These studies are relevant to human disease
because human tumours clearly express activin A and B and
levels of INHBA expression correlate with mortality. Overall,
our results suggest that a systemic activin-targeting
therapeutic strategy in combination with anti-cancer agents
will be necessary to combat PDAC and its associated fatal
wasting syndrome.
Our observation that the PDAC induced activin A and
activin B in multiple host organs has implications for design-
ing strategies to reduce activin signalling. First, both the circu-
lating activin and endogenous activin should be targeted to
achieve stronger inhibition. Although the soluble receptor
ACVR2B/Fc can block the circulating activins and inhibit para-
crine and endocrine signalling, it cannot prevent endogenous
activin from initiating autocrine signalling due to its inability
to bind cell surface heparin-sulfated proteoglycans.48,49 Such
endogenous activin and autocrine signalling may indeed play
an important part in muscle wasting.
Targeting upstream inducers of activin could also prevent
activin-mediated wasting. Activin A can induce INHBB (activin
B) expression, through a feed-forward, SMAD-dependent
mechanism.50 Thus, one might speculate that organ activins
induced in response to PDAC tumour were the result of
tumour-derived activins. However, while ACVR2B/Fc adminis-
tration alleviated cachexia in the orthotopic mouse model, it
did not alter the expression levels of Inhba and Inhbb in the
organs examined. This suggests that organ activin induction
is not via feed-forward endocrine activin loop; instead, other
factors released by the tumour are responsible for the induc-
tion, as illustrated in our myoblast/myotube cultures with
PDAC CM. The promoters of INHBA and INHBB demonstrate
quite different activity and transcription factor binding sites,
suggesting that each might be induced by different molecular
stimuli and signalling pathways. Identifying and targeting
those pathways could offer gene-specific means to prevent
endogenous activin A vs. activin B production.
ACVR2B/Fc has a broad spectrum of ligand binding beyond
activins that includes myostatin, activin, GDF11, and other
TGF-β family ligands, raising concerns of off-target effects.
To overcome this issue, Chen et al. developed antagonists
specific to activin A vs. activin A and B.51,52 The use of the an-
tagonist that targeted both activin A and activin B resulted in
a greater increase in muscle mass than activin A -only
targeting. In this context, our finding of a systemic induction
of activin B in addition to activin A in PDAC cachexia is signif-
icant. In fact, while activin A was induced in some of the or-
gans we examined, activin B was consistently induced in all
(Figure 3A and B). However, like the ACVR2B/Fc, the antago-
nists that Chen et al. generated only block circulating activins
Table 1 Tumour INHBA but not INHBB expression is increased in pancreatic cancer revealed by Oncomine database
Study Comparison Gene rank % tile P value t-test Fold change
Badea Pancrea PDAC vs. normal 4 Top 1% 1.68E-20 13.27 15.87
Bittner Multi-cancer PDAC vs. all cancer 29 Top 1% 2.01E-06 6.40 3.02
Ramaswarny Multi-cancer PDAC vs. all cancer 129 Top 2% 2.20E-05 5.60 4.36
London PDAC vs. normal 512 Top 10% 2.00E-03 5.35 33.50
Lacobuzio-Donahue Pancras PDAC vs. normal 962 Top 7% 3.00E-03 4.44 12.19
Pei Pancreas PC vs. normal 1227 Top 7% 3.27E-05 5.04 8.95
PDAC, pancreatic ductal adenocarcinoma.
Table 2 Relationship between PDAC tumour gene expression abundance
vs. survival in the TCGA pancreatic adenocarcinoma database, adjusted
for age, by the univariate Cox proportionate hazards (CoxPH) model









Bold text indicate statistically significant results.
PDAC, pancreatic ductal adenocarcinoma; TCGS, The Cancer Ge-
nome Atlas.
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and endocrine signalling but not the endogenous ones.52
Therefore, newer generations of antagonists targeting auto-
crine activin A and activin B signalling are needed to achieve
more potent effects.48,49,52
Activin blockade was effective here in reducing weight loss
but not always in increasing survival. In the present study, we
used two murine PDAC models, orthotopic implantation of
activinlow and activinhigh cell lines. ACVR2B/Fc was less effec-
tive in activinhigh than in activinlow in terms of survival benefit.
This result suggests that with more activin, perhaps a higher
dose of ACVR2B/Fc is necessary to be effective. Alternatively,
higher levels of Inhba expression in tumour may either reflect
or confer a more aggressive phenotype on the tumour itself,
and this would in turn pose a more profound impact on the
host. Such effects have been observed experimentally in
other in vitro and murine studies.16,21,53 These distinctions
and their relevance to the human condition require further
investigation. Of course, the lack of survival benefit in this
study could also be due to the lack of chemotherapy and
other clinical treatment. Such pre-clinical considerations must
be a focus of future studies in PDAC, given that activin recep-
tor inhibition prolongs survival dramatically in combination
with chemotherapy.47 Alternatively, a limitation of this ap-
proach could be the lesser protection of cardiac muscle vs.
skeletal muscle with activin blockade54 or the requirement
for inhibition of autocrine signalling in other yet unknown
organs.
The primary focus of most cancer cachexia research has
been skeletal muscle. Muscle represents more than 40% of
body weight, and thus, its wasting accounts for a large part
of body weight loss in cachexia. Other organs also waste,
however, including cardiac muscle and adipose tissue, two
Figure 9 Survival of patients according to expression of activin family genes in pancreatic tumours. Gene expression vs. survival in the TCGA pancreatic
adenocarcinoma data set. Ualcan.path.uab.edu accessed on 31 October 2018.
Systemic activin in PDAC cachexia 1097
DOI: 10.1002/jcsm.12461
Journal of Cachexia, Sarcopenia and Muscle 2019; 10: 1083–1101
organs that clearly play an important role in cachexia and
pancreatic cancer outcomes.55–59 Here, we observed wasting
of skeletal muscle, heart, fat, and multiple other organs, as
well as activin induction in most of those organs. Mice with
skeletal muscle-specific activin inhibition here showed pre-
served body weight with both activinlow and activinhigh tu-
mours but did not show prolonged survival, unlike WT mice
bearing the same activinlow tumours and treated with
ACVR2B/Fc. Two possible explanations for this discrepancy in-
clude (i) a critical role for activin signalling in other tissues, in-
cluding heart and fat, which might or might not be achieved
with systemic activin blockade but clearly not by transgene-
produced muscle-specific inhibition or (ii) a greater intrinsic
propensity for cancer death in mice with the dominant nega-
tive ACVR2B transgene, perhaps due to lower adipose
mass.43 Further studies would be required to distinguish
these possibilities.
Finally, our analysis of human tumours and available data
sets indicate specificity of activin isoforms and family mem-
bers in the pathogenesis of PDAC and its associated cachexia.
RNAseq data from TCGA showed a positive association of
only tumour activin A expression on mortality and not for
genes encoding Inhibin-alpha, follistatin and related proteins,
activin B, or receptors ACVR1B, ACVR1C, ACVR2A, and
ACVR2B (not shown), despite empirical evidence of certain
of these receptors influencing tumour phenotype.60–63 More-
over, RNA expression of the closely related proteins,
myostatin, and GDF-11 in tumours was actually associated
with reduced mortality, despite their ability to induce sys-
temic wasting.64,65 These results suggest highly context-
Figure 10 Proposed framework illustrating the systemic activin response to pancreatic cancer.
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specific roles of these factors in PDAC disease progression
and mortality. Finally, the use of targeting strategies that
non-specifically bind all of these family members (as does
ACVR2B/Fc) or their shared receptors (e.g. antibodies to
ACVR2B or ACVR2A) rather than binding activin A or activin
B selectively might ablate both the positive and negative ac-
tivities of this family in PDAC.
In summary, our study demonstrates that PDAC induces
cachexia involving multiple organs. This effect is mediated
by tumour-derived activins and other cachectic factors that
are released systemically and in turn stimulate a systemic or-
gan response that includes induction of endogenous activin A
and activin B. While soluble activin receptor ACVR2B/Fc can
block this circulating, endocrine activin, it has only a limited
capability of blocking autocrine activin signalling and might
non-specifically ablate positive effects of certain other ligands
(Figure 10). The tumour-derived, activin-inducing factors
have yet to be identified; however, finding novel agents that
block production of all activins or that inhibit activin selec-
tively is necessary to provide more effective therapy for PDAC
cachexia.
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